Lufotrelvir: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 58 patientsc19early.org

Lufotrelvir for COVID-19

Serious outcome risk
Lufotrelvir
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−22%
Mortality (1)−22%
RCTs (1)−22%
Late (1)−22%
00.511.5+
← Lufotrelvir
reduces riskIncreased
risk →
c19early.org
October 2026

Lufotrelvir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.989/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Grandits (DB RCT)44%0.56 · 0.29–1.10no disch.9/3213/26
Late treatment44%0.56 · 0.29–1.109/3213/2644% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.094
All studies44%0.56 · 0.29–1.109/3213/2644% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.09400.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.989/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →
c19early.org
October 2026

Lufotrelvir COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Grandits (DB RCT)−22%1.22 · 0.50–2.98death9/326/26
Late treatment−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−22%1.22 · 0.50–2.989/326/2622% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Lufotrelvir
reduces riskLufotrelvir
increases risk →